Pharmaceuticals, Biotechnology and Life Sciences
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…
GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, has initiated a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D).
GeNeuro and Servierhave set up a study they named ANGEL-MS, which is a long-term extension study for patients with multiple sclerosis…